The stock score is primarily driven by strong technical indicators and solid financial performance, despite valuation concerns due to a negative P/E ratio. The attractive dividend yield partially offsets these valuation issues. The absence of earnings call data and corporate events means these factors did not influence the score.
Positive Factors
Strong Balance Sheet
A robust balance sheet with high equity and low leverage provides durable financial flexibility: it supports funding of portfolio transactions, cushions downturns, and reduces refinancing risk, enabling sustained capital allocation to strategic investments and distributions.
Healthy Profitability & Margins
Sustained gross and operating margins indicate effective cost management and profitable portfolio composition. Margin resilience improves internal cash generation potential and supports long-term return of capital or reinvestment even if top-line growth fluctuates.
Improving Cash Generation
A recent shift to positive operating cash flow and improving free cash flow suggest better cash conversion, which is fundamental for durable dividend capacity, funding selective exits or bolt-on investments, and lowering reliance on external financing.
Negative Factors
Cash Flow Volatility
Volatile operating and free cash flows create uncertainty in funding ongoing operations, dividend sustainability, and the ability to support portfolio companies. This volatility can force reliance on asset sales or external financing, adding execution risk.
Revenue Volatility & Recent Decline
Significant revenue swings and a recent drop undermine predictability of earnings and valuations of holdings. For a holding company, unstable top-line performance complicates cash planning and reduces visibility on distributable earnings over the medium term.
Holding Structure & Small Scale
As a small-scale investment holding, the company depends on returns from portfolio companies and external managers. Limited operational footprint and concentration risk reduce direct control over outcomes and increase sensitivity to individual asset performance.
MPH Health Care AG (93M1) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€83.27M
Dividend Yield5.31%
Average Volume (3M)1.46K
Price to Earnings (P/E)―
Beta (1Y)0.16
Revenue Growth180.19%
EPS Growth-196.45%
CountryDE
Employees2
SectorFinancial
Sector Strength70
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,281,384
10 Day Avg. Volume2,127
30 Day Avg. Volume1,460
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)0.35
Price to Sales (P/S)15.83
P/FCF Ratio53.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.9
Revenue Forecast (FY)€24.74M
MPH Health Care AG Business Overview & Revenue Model
Company DescriptionMPH Health Care AG, an investment company, engages in the healthcare business in Germany. It produces and sells medicinal products for the therapies of cancer, HIV, and other chronic diseases. The company also offers medical aesthetic treatments; and develops and sells pharmaceutical and medical products; and provides related services, as well as medical devices for the aesthetic surgery and cosmetic dermatology. In addition, it is involved in the provision of cytostatic solutions; and real estate activities. The company was formerly known as MPH Mittelständische Pharma Holding AG and changed its name to MPH Health Care AG in 2017. The company was founded in 2008 and is based in Berlin, Germany. MPH Health Care AG is a subsidiary of Magnum AG.
How the Company Makes MoneyMPH Health Care AG generates revenue through multiple streams, primarily from the sale of its medical devices and health management software. The company partners with hospitals, clinics, and healthcare providers to supply its products, often entering long-term contracts that ensure a steady flow of income. Additionally, MPH Health Care AG earns revenue from its pharmaceutical division by marketing and distributing proprietary drugs, which are often developed in collaboration with research institutions. Strategic partnerships with other healthcare entities and participation in government health programs also contribute to the company's financial performance, allowing it to expand its market reach and enhance product development capabilities.
MPH Health Care AG Financial Statement Overview
Summary
MPH Health Care AG demonstrates strong profitability and financial stability, with a solid equity position and effective cost management. However, revenue fluctuations and cash flow volatility are areas of concern. Continued focus on generating consistent cash flows will be crucial for maintaining financial health.
Income Statement
78
Positive
MPH Health Care AG has shown improvement in key profitability metrics over recent years. The gross profit margin is strong, and there is a consistent net profit margin indicating profitability. However, revenue has fluctuated significantly, with a notable decline in 2024. Despite these fluctuations, EBIT and EBITDA margins remain healthy, reflecting effective cost management.
Balance Sheet
85
Very Positive
The company's balance sheet is robust, with a high equity ratio and a low debt-to-equity ratio, indicating financial stability. The return on equity is impressive, reflecting efficient use of shareholder funds. The company has managed its liabilities well, maintaining a solid stockholders' equity position, which suggests strong financial health.
Cash Flow
72
Positive
Cash flow analysis reveals some concerns, particularly with operating cash flow being negative in recent years, although it has turned positive in the latest period. The free cash flow shows significant volatility, but recent improvements in free cash flow growth are positive. The ratios indicate a need for better alignment of cash flow generation with net income.
Breakdown
TTM
Dec 2024
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Income Statement
Total Revenue
-72.59M
6.11M
7.24M
6.85M
4.36M
-9.02M
Gross Profit
-72.59M
6.11M
125.94M
6.80M
4.01M
-9.45M
EBITDA
-37.87M
33.32M
30.36M
29.68M
-9.05M
-71.00M
Net Income
-115.23M
32.04M
29.54M
29.11M
-8.96M
-70.38M
Balance Sheet
Total Assets
218.84M
291.06M
266.35M
236.99M
198.00M
210.71M
Cash, Cash Equivalents and Short-Term Investments
2.65M
1.20M
5.10M
3.82M
4.44M
4.23M
Total Debt
11.72M
10.56M
13.05M
12.99M
4.05M
7.62M
Total Liabilities
13.72M
13.19M
15.39M
15.57M
5.69M
9.45M
Stockholders Equity
205.12M
277.87M
250.97M
221.42M
192.31M
201.26M
Cash Flow
Free Cash Flow
1.02M
1.83M
-2.02M
-170.41K
-1.28M
-3.36M
Operating Cash Flow
3.59M
1.83M
-2.02M
-164.79K
-1.28M
-3.36M
Investing Cash Flow
4.10M
3.40M
5.40M
-8.96M
6.37M
12.83M
Financing Cash Flow
-6.85M
-7.70M
7.74M
-3.02M
-3.61M
-10.90M
MPH Health Care AG Technical Analysis
Technical Analysis Sentiment
Negative
Last Price22.10
Price Trends
50DMA
22.72
Negative
100DMA
21.68
Negative
200DMA
19.84
Negative
Market Momentum
MACD
-0.74
Positive
RSI
24.36
Positive
STOCH
7.37
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:93M1, the sentiment is Negative. The current price of 22.1 is above the 20-day moving average (MA) of 21.74, below the 50-day MA of 22.72, and above the 200-day MA of 19.84, indicating a bearish trend. The MACD of -0.74 indicates Positive momentum. The RSI at 24.36 is Positive, neither overbought nor oversold. The STOCH value of 7.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:93M1.
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 13, 2025